Clinical Trial: NCT04539938
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Seagen, a wholly owned subsidiary of Pfizer |
| Information Provided By: | Seagen Inc. |
| Last Update Posted: | 2026-03-23 |
Study Overview
Brief Summary
This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer.
Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and T-DXd.
Official Title
Conditions
Intervention / Treatment
- Drug: tucatinib
- Drug: trastuzumab deruxtecan
Other Study ID Numbers
- SGNTUC-025
- C4251006
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Seagen, a wholly owned subsidiary of Pfizer |
| Information Provided By: | Seagen Inc. |
| Last Update Posted: | 2026-03-23 |
Study Overview
Brief Summary
This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer.
Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and T-DXd.
Official Title
Conditions
Intervention / Treatment
- Drug: tucatinib
- Drug: trastuzumab deruxtecan
Other Study ID Numbers
- SGNTUC-025
- C4251006